T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$1.82B |
| 2 |
Sea Limited
SE
|
+$1.38B |
| 3 |
Cisco
CSCO
|
+$1.16B |
| 4 |
Netflix
NFLX
|
+$1.14B |
| 5 |
Ingersoll Rand
IR
|
+$1.03B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.54B |
| 2 |
Amazon
AMZN
|
+$1.75B |
| 3 |
Amphenol
APH
|
+$1.65B |
| 4 |
KLA
KLAC
|
+$1.5B |
| 5 |
Xcel Energy
XEL
|
+$1.38B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.6% |
| 2 | Financials | 11.17% |
| 3 | Healthcare | 11.1% |
| 4 | Communication Services | 10.25% |
| 5 | Consumer Discretionary | 10.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2601
Cytek Biosciences
CTKB
$566M
| $351K | ﹤0.01% |
80,142
+10,349
| +15% | +$48.9K |
|
2602
N-able
NABL
$844M
| $351K | ﹤0.01% |
75,149
+7,273
| +11% | +$40.6K |
|
2603
CEVA Inc
CEVA
$831M
| $350K | ﹤0.01% |
18,729
+5,049
| +37% | +$106K |
|
2604
Claros Mortgage Trust
CMTG
$290M
| $350K | ﹤0.01% |
146,934
+32,909
| +29% | +$85.2K |
|
2605
Asure Software
ASUR
$242M
| $348K | ﹤0.01% |
40,450
+3,458
| +9% | +$30.5K |
|
2606
Akebia Therapeutics
AKBA
$338M
| $347K | ﹤0.01% |
249,155
+36,475
| +17% | +$50.1K |
|
|
NUTX
2607
Nutex Health
NUTX
$967M
| $347K | ﹤0.01% |
3,648
+1,588
| +77% | +$195K |
|
2608
MediaAlpha
MAX
$746M
| $345K | ﹤0.01% |
37,076
+6,062
| +20% | +$59.7K |
|
2609
Mativ Holdings
MATV
$479M
| $344K | ﹤0.01% |
39,514
+7,711
| +24% | +$88.4K |
|
2610
Miller Industries
MLR
$577M
| $344K | ﹤0.01% |
7,546
+909
| +14% | +$38.8K |
|
2611
Consolidated Water Co
CWCO
$472M
| $343K | ﹤0.01% |
10,332
+1,408
| +16% | +$50.5K |
|
2612
HighPeak Energy
HPK
$838M
| $343K | ﹤0.01% |
49,705
+7,842
| +19% | +$41.2K |
|
|
MAGN
2613
Magnera Corp
MAGN
$493M
| $343K | ﹤0.01% |
36,012
+4,735
| +15% | +$60.5K |
|
2614
Evolent Health
EVH
$371M
| $342K | ﹤0.01% |
149,821
+15,408
| +11% | +$48.9K |
|
2615
CorMedix
CRMD
$564M
| $341K | ﹤0.01% |
50,130
+7,584
| +18% | +$56.1K |
|
|
SVC
2616
Service Properties Trust
SVC
$1.05B
| $341K | ﹤0.01% |
50,233
+10,472
| +26% | +$109K |
|
2617
KVH Industries
KVHI
$171M
| $339K | ﹤0.01% |
37,763
| – | – |
|
2618
Peoples Financial Services
PFIS
$718M
| $339K | ﹤0.01% |
6,340
+767
| +14% | +$40.4K |
|
2619
SIGA Technologies
SIGA
$240M
| $339K | ﹤0.01% |
63,337
+16,993
| +37% | +$106K |
|
2620
Telos
TLS
$331M
| $339K | ﹤0.01% |
80,902
+12,966
| +19% | +$61.3K |
|
2621
iShares Biotechnology ETF
IBB
$9.45B
| $338K | ﹤0.01% |
2,000
| – | – |
|
2622
Bioventus
BVS
$889M
| $337K | ﹤0.01% |
36,811
+12,163
| +49% | +$102K |
|
2623
Corsair Gaming
CRSR
$1.1B
| $337K | ﹤0.01% |
60,619
+10,046
| +20% | +$55.4K |
|
2624
ACNB Corp
ACNB
$646M
| $335K | ﹤0.01% |
6,997
+664
| +10% | +$32.7K |
|
2625
Clearfield
CLFD
$401M
| $335K | ﹤0.01% |
12,642
+2,024
| +19% | +$61.7K |
|
Similar funds
T. Rowe Price Associates's Q1 2026 Portfolio in Review
As of Q1 2026, T. Rowe Price Associates held 3,202 positions worth $865B, down 6.7% from $927B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
T. Rowe Price Associates's Q1 2026 filing shows 115 new, 2,022 increased, 804 reduced and 71 closed positions. Its largest new stake was Cenovus Energy: 23,907,299 shares worth $634M. The largest sale was Microsoft, an estimated $3.54B.
By sector, the portfolio is most concentrated in Technology at 34% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q1 2026 buy was Cenovus Energy: 23,907,299 shares worth $634M.
- T. Rowe Price Associates added most to Advanced Micro Devices in Q1 2026, an estimated $1.82B increase.
- T. Rowe Price Associates's biggest Q1 2026 reduction was Microsoft, cutting an estimated $3.54B.
- T. Rowe Price Associates fully exited CyberArk in Q1 2026, selling an estimated $251M.
- T. Rowe Price Associates's ten largest holdings make up 34% of its $865B portfolio in Q1 2026.
- T. Rowe Price Associates opened 115 new positions and closed 71 in Q1 2026.
- T. Rowe Price Associates's portfolio value fell 6.7% quarter-over-quarter to $865B.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.